Cartilage Regeneration Treatment Decision
Who Is Suitable
for ChondroFiller®?
ChondroFiller® is not right for every cartilage problem. Use this page as a guide before booking; the final decision is made at consultation with Professor Paul Lee after imaging review and clinical assessment.
Reviewed byProf Paul Lee MBBch, FRCS (Tr & Orth), PhDLast reviewed 1 May 2026Quick Answer
ChondroFiller® as an injection may be suitable for adults with a focal cartilage defect identified on imaging, typically up to around 6 cm², with stable joint mechanics and a goal of joint preservation. It is less suitable for widespread bone-on-bone arthritis, major untreated malalignment, or defects significantly larger than 6 cm² (where the Liquid Cartilage™ keyhole surgery or another cartilage repair procedure may be more appropriate). Imaging-led assessment is essential before any decision.
Strong Indicators
Good candidates may include
Focal cartilage defect on imaging
A discrete cartilage lesion identified on MRI (typically up to 6 cm²) in the knee, hip, shoulder, ankle, elbow, foot, hand or wrist. The defect being contained is the foundation of a successful regenerative scaffold.
Cartilage damage after injury
Post-traumatic chondral lesions, osteochondritis dissecans (OCD), or cartilage damage following meniscal injury or ligament reconstruction. ChondroFiller® supports defect-targeted regeneration where the wider joint is otherwise sound.
Early or localised joint degeneration
Localised cartilage loss in an otherwise well-preserved joint, where the goal is to address the defect before it progresses to widespread arthritis. Joint preservation, not joint replacement.
Stable joint mechanics
No untreated ligament instability, no significant malalignment, no meniscal deficit driving the wear. ChondroFiller® addresses the defect, but a mechanically unstable joint will keep re-injuring the new tissue.
Realistic expectations
Understanding that ChondroFiller® supports regeneration but does not guarantee it, that improvement builds over six to twelve months, and that some defects respond better than others. ChondroFiller® is not a cure for arthritis.
Willing to follow the rehab plan
Comfortable with activity modification for two to four weeks, optional onward physiotherapy, and a six-week clinical follow-up. New tissue establishes more reliably when the joint is given room to settle.
Where Caution Is Needed
Patients who may need caution
These are not absolute contraindications, but they warrant a careful conversation before treatment. In many of these situations we recommend an alternative pathway.
Advanced bone-on-bone arthritis
End-stage osteoarthritis where cartilage has been substantially lost across a wide area. A defect-targeted scaffold has little to anchor into. We may discuss the Liquid Cartilage™ keyhole-surgery pathway (our proprietary ChondroFiller + MSC co-delivery technique) for selected complex cases, an Arthrosamid® cushion for symptom relief, or knee replacement depending on the case.
Defect significantly larger than 6 cm²
Above the size limit for a stand-alone injection. The Liquid Cartilage™ keyhole-surgery pathway (ChondroFiller + MSC co-delivery in a single arthroscopic procedure) is often the better answer; in some cases another cartilage repair procedure such as MACI/ACI or osteochondral autograft transfer is more appropriate.
Untreated joint instability or malalignment
Untreated ACL injury, meniscal deficit, varus/valgus malalignment, or patellar maltracking. Regenerated cartilage on an unstable platform tends to fail. We may suggest correcting the mechanical problem first.
Active infection
Any active infection, in the joint or systemically, is a reason to defer ChondroFiller®. We treat the infection first and reassess.
Unrealistic expectation of guaranteed regeneration
ChondroFiller® supports regeneration, but outcomes vary by defect size, location, surrounding cartilage quality and patient biology. Patients who expect a guaranteed cure, complete pain relief or zero variability are not good candidates for any regenerative treatment.
Immunosuppression or poorly controlled diabetes
Conditions that significantly raise infection risk warrant a tailored discussion. Most patients can still proceed safely with appropriate planning, but the conversation is more careful.
Pre-Treatment Assessment
What we check before recommending ChondroFiller®
Imaging review
Recent MRI is essential — ChondroFiller® is a defect-targeted scaffold and we need to map the cartilage defect before we can recommend it. We can arrange an MRI if you do not have one. X-rays add context on joint space and alignment.
Defect characterisation
Size, depth, location, surrounding cartilage quality, and whether the defect is contained. Box requirement (one, two or three) is decided here. Defects significantly larger than 6 cm² are routed to a different pathway.
Joint mechanics
Ligament stability, meniscal status, alignment, patellar tracking (for knee cases). A mechanically unstable platform tends to re-injure regenerated tissue. We may recommend addressing instability first.
Conservative-treatment and surgical history
What you have tried — physiotherapy, injections, previous arthroscopy, microfracture, MACI/ACI. Previous procedures do not rule out ChondroFiller®; they shape the recommendation.
Comorbidity and medication review
Immunosuppression, diabetes control, anticoagulation, recent or active infection. Any of these can change the safety profile or the timing of treatment.
Your goals and expectations
What you want from treatment, what counts as a good outcome, over what timeframe. We will not offer ChondroFiller® where expectations cannot be matched to what a regenerative scaffold can do.
Advanced Disease
Bone-on-bone arthritis and large defects
ChondroFiller® as an injection is unlikely to help in end-stage, bone-on-bone disease. Where cartilage has been substantially lost across a wide area, a defect-targeted scaffold has little to anchor into. Regeneration depends on contained defects with healthy surrounding cartilage.
In these cases the alternatives include the Liquid Cartilage™ keyhole-surgery pathway (our proprietary technique combining ChondroFiller® with MSC co-delivery in a single arthroscopic procedure) for selected complex cases, an Arthrosamid® injection where the goal is symptom relief rather than regeneration, or a knee replacement conversation where the joint surface is no longer salvageable.
For larger but still focal defects above the typical 6 cm² threshold for a stand-alone injection, the Liquid Cartilage™ surgical pathway combines the ChondroFiller® scaffold with biologic augmentation in a single keyhole procedure, and is often the better answer. Other cartilage repair options such as MACI/ACI or osteochondral autograft transfer may also be appropriate. The imaging review at consultation is what tells us which pathway fits.
Five Questions, Three Minutes
Take the ChondroFiller® pathway self-assessment
A short questionnaire that maps your goals and joint history to one of four ChondroFiller® pathways — Prevention, Regeneration, Combination or Support. Use it before booking a discovery call so we start from a shared understanding.
Suitability for ChondroFiller®
Frequently asked questions
Who is the ideal candidate for ChondroFiller®?
The ideal candidate is an adult with a focal cartilage defect identified on imaging, stable joint mechanics, realistic expectations about a regenerative timeline, and a desire to preserve the joint rather than replace it. ChondroFiller® works best where the defect is contained, the surrounding cartilage is reasonably healthy, and any underlying instability or malalignment has been addressed.
Can I have ChondroFiller® as an injection if I have bone-on-bone arthritis?
Advanced bone-on-bone osteoarthritis is one of the situations where the ChondroFiller® injection is unlikely to deliver meaningful regeneration. Once the joint surface has been substantially lost across a wide area, a defect-targeted scaffold has little to anchor into. We may discuss the Liquid Cartilage™ pathway (our proprietary keyhole-surgery technique combining ChondroFiller® with MSC co-delivery) for selected complex cases, or a knee replacement conversation where appropriate. Imaging at consultation is what tells us which side of the line you sit on.
What if my cartilage defect is larger than 6 cm²?
ChondroFiller® is best suited to focal defects up to around 6 cm² as a stand-alone injection. Larger or more complex defects often benefit from the Liquid Cartilage™ pathway — our proprietary keyhole-surgery technique combining ChondroFiller® with MSC (medicinal signalling cells) co-delivery in a single arthroscopic procedure. Some cases are better addressed with MACI/ACI or osteochondral autograft transfer instead. The decision is made at consultation after imaging review.
Can ChondroFiller® treat multiple cartilage defects at once?
Yes. Box pricing reflects this — most patients are treated with a single box for one defect, but two or three boxes can be used to address larger, multi-compartment or bilateral cases in a single appointment. See the ChondroFiller® cost guide for the box-tier breakdown.
What if I have had previous joint surgery?
Previous arthroscopy, microfracture, meniscal repair or ligament reconstruction does not rule out ChondroFiller® — in fact, ChondroFiller® is often considered after these procedures when symptoms persist due to residual cartilage damage. The picture depends on the current state of the joint, not the history alone. Bring imaging and operative reports to the consultation.
Will you tell me honestly if I am not a good candidate?
Yes. We routinely decline ChondroFiller® cases where the chance of meaningful regeneration is low, or where another treatment is the better answer. A clinic willing to say no is a clinic selecting for outcomes. If ChondroFiller® is not right, we will tell you what is — whether that is a different cartilage repair pathway, a long-acting Arthrosamid® injection for symptom relief, or a knee replacement conversation.
Book a ChondroFiller® Assessment – London
Natural cartilage regeneration starts with the right defect, the right operator, and the right plan.
Learn More about ChondroFiller
Deep dive into our clinical resources and patient guides.
Cost in the UK
ChondroFiller® cost in the UK from £3,000, what is included and why prices vary.
Suitability
Who is suitable for ChondroFiller® as an injection, and who may need caution.
Clinical Evidence
IKDC, Harris Hip Score and MOCART MRI outcomes for ChondroFiller® cartilage regeneration.
Self-Assessment
Five-question ChondroFiller® pathway self-assessment for Prevention, Regeneration, Combination, or Support.
In London
Private ChondroFiller® cartilage repair at our Harley Street clinic.
Liquid Cartilage™ Surgery
Our proprietary keyhole-surgery technique combining ChondroFiller® with MSC co-delivery in a single procedure, for larger or more complex cartilage defects. £9,800.
ChondroFiller vs Arthrosamid
Cartilage regeneration vs joint cushioning, two very different injections.
ChondroFiller vs Hyaluronic Acid
Structural scaffold for cartilage regeneration vs joint-lubricant viscosupplement.
ChondroFiller vs Microfracture
ChondroFiller® regeneration compared to microfracture surgery for cartilage defects.
ChondroFiller vs MACI
ChondroFiller® scaffold compared to matrix-induced autologous chondrocyte implantation.
ChondroFiller vs ACI
ChondroFiller® scaffold compared to the original autologous chondrocyte implantation technique.
ChondroFiller vs PRP
ChondroFiller® cartilage regeneration compared to platelet-rich plasma injection.
ChondroFiller vs Stem Cells
ChondroFiller® compared to stem cell and biologic regenerative treatments.
ChondroFiller vs Knee Replacement
Where ChondroFiller® may help preserve the joint and where replacement is the right answer.
ChondroFiller® Injection
Cartilage Regeneration Overview
ChondroFiller® is a registered trademark of Meidrix Biomedicals GmbH. London Cartilage Clinic is not affiliated with or endorsed by Meidrix Biomedicals.